Background
Introduction
address the question whether RV/TLC should be taken into account when LCI was adopted for assessment of ventilatory heterogeneity in patients with bronchiectasis.
Methods

Patients
Enrollment of consecutive bronchiectasis patients was conducted between March 2014 and May 2016. Diagnosis of bronchiectasis was made according to chest HRCT, effective within 12 months. Patients were aged 18 years or greater, and had no exacerbation for more than 4 weeks. Exacerbation should meet three or more criteria (persisting for >24hrs): significantly increased cough frequency; increased sputum purulence/volume; dyspnea; fever; hemoptysis; exercise intolerance; chest pain; increased pulmonary infiltration [6, 14] . Exclusion criteria were antibiotics use within 4 weeks, malignancy, and failure to undergo measurements. To analyze discriminative performance in real-world settings, concomitant respiratory diseases (e.g. asthma) were not excluded.
Study protocol approval was obtained from Ethics Committee of The First Affiliated Hospital of Guangzhou Medical University. All patients gave written informed consent.
Study design
The discriminative performance of LCI and RV/TLC%, and their association with clinical parameters of bronchiectasis were evaluated. Assessment included history inquiry, multiplebreath washout test, spirometry, and sputum culture. All baseline measurements were performed within 12 months of the chest HRCT assessment. To determine how ventilation heterogeneity or air trapping correlated with bronchodilator responses, we stratified according to LCI and RV/TLC (see details below). Our study design complied with the STROBE guideline (S1 Text).
Clinical assessments
A radiologist with working experience of more than 10 years evaluated the CT scans and graded the radiological severity. Chest HRCT score was evaluated using modified Reiff score (0-6 points, mild bronchiectasis; 7-12 points, moderate bronchiectasis; 13-18 points, severe bronchiectasis) [6, 14] . Dyshomogeneity (mosaicism), cystic bronchiectasis (denoted the presence of cystic changes of the dilated bronchi on chest HRCT), and the number of bronchiectatic lobes were evaluated.
A full description of the MBW is available in the Online Supplement text (S2 Text). MBW [6, 15] with nitrogen as tracer gas was performed before spirometry, to derive the LCI values. Reference values of spirometry were derived from validated equations [16] . Following all MBW maneuvers which measured the functional residual volume, patients underwent slow vital capacity measurement in which an inspiratory and expiratory maneuver was involved, which was applied to calculate the total lung capacity and RV/TLC. The maximal values of forced vital capacity (FVC) and forced expiratory volume in one second (FEV 1 ) were reported for spirometry. Bronchial dilation test was performed within the same day of LCI and RV/TLC measurement, in a subgroup of patients (concurrent bronchodilation test cohort) with FEV 1 <80% predicted to minimize ceiling bronchodilator effects [14] . Inhaled long-acting beta-agonists or muscarinic receptor antagonists should be withheld for at least 12 hours, whereas short-acting beta-agonists or muscarinic receptor antagonists were withheld for at least 8 hours before bronchodilation test. Given small sample sizes, we also compared bronchodilator responses in patients who had ever undergone bronchodilation test within 2 years. Data were pooled (concurrent & previous bronchodilation test cohort) to increase statistical power of identifying different bronchodilator responses.
Following removal of oral debris, fresh sputum was obtained within 2 hours of sampling at initial visits. Bacterial (e.g. Pseudomonas aeruginosa) colonization was defined as two or more occasions (more than three months apart) with identical pathogenic bacteria being isolated from sputum within the nearest one year [16, 17] . Bronchiectasis Severity Index (BSI) was employed to measure bronchiectasis severity, with 0-4, 5-8, and 9 points or greater corresponding to mild, moderate and severe bronchiectasis, respectively [17] .
Statistical analysis
Mean ± standard deviation or median (interquartile range) was expressed for numerical data, and compared with independent t-test or Mann-Whitney test. No. (%) was used for describing dichotomous data, and compared using chi-square tests.
LCI was normalized with RV/TLC (nLCI, calculated as dividing the LCI by RV/TLC) to assess whether it would improve discriminative performance of LCI. We adopted receiver operation characteristic (ROC) curve to compare how RV/TLC, LCI and nLCI discriminated moderate-to-severe from mild bronchiectasis, and mild-to-moderate from severe bronchiectasis according to BSI score. The area under curve (AUC), 95% confidence intervals (95%CI), sensitivity, specificity, accuracy and cut-off were calculated. The AUC was compared with MedCalc (MedCalc Inc., Ostend, Belgium). Chi-square test was applied to determine the consistency for dichotomous results of RV/TLC and LCI (lower and upper 50 th percentile). We assessed the correlation between RV/TLC and LCI, using partial correlation model with adjustment for age, sex, body-mass index and baseline FEV 1 % predicted. We determined clinical variable attributes' impacts on LCI, RV/TLC and nLCI using generalized linear mixed model, with factors of sex, sputum bacteriology (Pseudomonas aeruginosa/ non-Pseudomonas aeruginosa colonized), cystic bronchiectasis (yes/no) and mosaicism (yes/ no) as factors, and covariates of the number of bronchiectatic lobes, HRCT total score, age and baseline FEV 1 % predicted for fitting fixed-effect estimates.
To determine whether bronchodilator responses differ with ventilation heterogeneity and hyperinflation, RV/TLC (high vs. low) and LCI (high vs. low) were dichotomized according to their medians among all patients. 
Results
Subject enrollment
Data from 127 out of 166 patients who underwent screening were analyzed. 42 and 47 patients underwent bronchodilation test at baseline and at least once within 2 years, respectively (Fig  1) . Bronchodilator response was evaluated in concurrent bronchodilation test cohort (n = 42) and pooled cohort (concurrent & previous bronchodilation test cohort, n = 88), respectively.
Clinical characteristics
Of 127 bronchiectasis patients, most were female and never-smokers. The median BSI was 6.0. Pseudomonas aeruginosa was isolated from~33% of cases. 85.8% of patients were never-smokers. 70% of patients had administered mucolytics within 6 months, but none was using inhaled antibiotics. Idiopathic and post-infectious constituted the most common etiologies. Asthma was deemed to be underlying causes in two patients (1.6%). Similar baseline characteristics were noted for concurrent and previous bronchodilation test cohorts, except for significant gender distribution. (Table 1) The discriminative power of LCI, RV/TLC, and nLCI Numerical data were presented as either mean ± standard deviation (SD) or median (interquartile range, IQR) as appropriate. No patient was regularly using inhaled, oral or systemic antibiotics. LCI: lung clearance index; RV/TLC: the ratio of residual volume to total lung capacity a This cohort referred to the bronchiectasis patients who had undergone bronchodilation tests within the same day of multiple-breath nitrogen washout test and spirometry (also selected from the whole bronchiectasis cohort). b This cohort referred to the bronchiectasis patients who had undergone bronchodilation tests within the previous 2 years (also selected from the whole bronchiectasis cohort). c Other pathogenic bacteria for all bronchiectasis patients included Haemophilus parainfluenzae (n = 8, 7.3%), Escherichia coli (n = 5, 4.5%), Klebsiella pneumoniae (n = 4, 3.6%), Serratia marcescens (n = 2, 1.8%), Streptococcus pneumoniae (n = 1, 0.9%), Moraxella catarrhalis (n = 1, 0.9%),
Achromobacter xylosoxidans (n = 1, 0.9%), Proteus mirabilis (n = 1, 0.9%), Haemophilus haemolyticus (n = 1, 0.9%) and Bordetella bronchiseptica (n = 1, 0.9%). d Most patients had ever used more than one category of medications within the last 6 months. e Dual underlying causes were determined in a minority of patients, thus the cumulative percentage was greater than 100%. Miscellaneous causes consisted of immunodeficiency, allergic bronchopulmonary aspergillosis, gastroesophageal reflux disease, asthma, diffuse panbronchiolitis, Kartagener syndrome, non-tuberculous mycobacteria disease, Young's syndrome, rheumatoid arthritis, lung sequestration syndrome, and lung malformation. * P values denoted the comparison between concurrent and historic bronchodilation test cohorts.
https://doi.org/10.1371/journal.pone.0183779.t001
comparable power in discriminating mild-to-moderate from severe bronchiectasis (AUC: 0.70 vs. 0.69, P = 0.839). The nLCI, however, did not confer additional discriminative performance compared with RV/TLC alone (P = 0.894) and was inferior to LCI (P = 0.020) in discriminating moderate-to-severe from mild bronchiectasis. Moreover, the nLCI had comparable discriminative performance with RV/TLC alone (P = 0.131) but was inferior to LCI (P<0.001) discriminating mild-to-moderate from severe bronchiectasis (Fig 2, Table B in S2 Text) . Moreover, LCI (AUC: 0.81, 95%CI: 0.73, 0.90) performed slightly better than RV/TLC (AUC: 0.72, 95%CI: 0.62, 0.82) in discriminating bronchiectasis patients with from without FEV 1 >80% predicted (P = 0.129). Again, adopting the nLCI did not contribute to improved discriminative performance compared with LCI (P = 0.261 for nLCI vs. RV/TLC). (Table C Table E in S2 Text) . Nevertheless, we did not find significant correlation between functional residual capacity and RV/TLC (r = 0.09, P = 0.30).
Both LCI and RV/TLC significantly were associated with HRCT score, age, FEV 1 % predicted, and cystic bronchiectasis (all P<0.001). LCI was associated with Pseudomonas aeruginosa colonization, and had a borderline association with mosaicism; whereas RV/TLC correlated with gender. The nLCI had slightly greater effect sizes than LCI and RV/TLC in terms of correlation with HRCT score (estimate: 0.67, 95%CI: 0.57, 0.77), Pseudomonas aeruginosa colonization (estimate: -1.65, 95%CI: -2.09, -1.21), and cystic bronchiectasis (estimate: 3.28, 95%CI: 2.81, 3.74). (Table 3 ) Furthermore, subgroup analyses according to bronchiectasis severity showed similar variable attributes' impacts on LCI, RV/TLC and nLCI (Tables F-H in  S2 Text) . RV/TLC: the ratio of residual volume to total lung capacity; nLCI: normalized lung clearance index. Concordance was compared between the subgroups with higher or lower than the median of LCI, RV/TLC, and the normalized LCI, respectively. Because there was no "gold standard" for dichotomizing the HRCT score, we compared the data by using the median score of 9. For LCI, "Low" denoted the values being equal to or lower than the median (14.6), whereas "high" indicated the values being higher than the median (14.6). For RV/TLC, "Low" denoted the values being equal to or lower than the median (41.5%), whereas "high" indicated the values being higher than the median (41.5%). For normalized LCI, "Low" denoted the values being equal to or lower than the median (35.6), whereas "high" indicated the values being higher than the median (35.6). All median levels were derived from the whole bronchiectasis patient cohort (n = 127). * Denoted the presence of cystic changes of the dilated bronchi on chest HRCT.
https://doi.org/10.1371/journal.pone.0183779.t002
Clinical characteristics of bronchiectasis when stratified by LCI and RV/ TLC 
Discussion
Main findings
MBW are simple and feasible for measuring ventilation heterogeneity and the functional residual volume. Despite growing application of LCI for bronchiectasis assessment, no study has mentioned the potential impacts of RV/TLC on analysis of LCI. Conventionally, raw LCI values have been consistently reported. This study comprehensively compared the discriminative performance of LCI and RV/TLC in bronchiectasis across the whole severity spectrum, and compared with the normalized parameter (nLCI). Furthermore, we compared bronchodilator responses by stratifying the LCI and RV/TLC. Overall, our findings justify the report of raw, but not normalized, values of LCI.
Interpretation
Historically, head-to-head comparisons of LCI and RV/TLC are lacking. The positive correlations between them might be primarily attributable to more aberrant airway architectures associated with greater disease severity. Findings from CF showed that LCI abnormality (84%) was more common than lung hyperinflation (58%) measured with residual volume in young children [18] , and that LCI was more sensitive than functional residual capacity to discriminate Pseudomonas aeruginosa plus other pathogenic bacteria infection in children [19] . However, in the study by Gustafsson et al [20] , LCI had greater sensitivity to detect abnormal lung structure which incorporated air trapping >30% and bronchiectasis in CF. Our study was the first to document that LCI conferred superior discriminative performance to RV/TLC for bronchiectasis assessment. Theoretically, gas trapping leading to hyperinflation is the consequence of increased bronchial wall thickness and decreased attenuation [21] which are associated with airway remodeling following recurrent infection and inflammation; whereas LCI correlated with airway mucus plugging (which had no significant impacts on airway obstruction) [21] and bronchial wall thickness [22] . Discordant changes in lung volume and LCI have been shown in bronchiectasis following chest physiotherapy which sought to mitigate mucus plugging [23] . Therefore, LCI might have greater discriminative performance and better correlation with clinical variables of bronchiectasis than hyperinflation indices such as RV/TLC. Normalization of LCI with RV/TLC did not contribute to improved discriminative performance or correlation with the clinical variables of bronchiectasis compared with either parameter alone. This indicated that the magnitude of hyperinflation did not significantly affect ventilation heterogeneity. In the study by Haidopoulou et al., adjustment of LCI with airway and/or equipment dead space did not improve the sensitivity in identifying early CF lung disease (which frequently included bronchiectasis) in children [24] . Thus, LCI was virtually unaffected by dead space volume, either from the respiratory tract or testing equipment. One might argue the numerically greater correlation of nLCI with clinical parameters; however, the priority of clinical relevance should be given to discriminative performance and concordance with other clinical variables. Our findings remained unchanged following stratification of For LCI, "Low" denoted the values being equal to or lower than the median (14.6), whereas "high" indicated the values being higher than the median (14.6).
For RV/TLC%, "Low" denoted the values being equal to or lower than the median (41.5%), whereas "high" indicated the values being higher than the median (41.5%). Significant bronchodilator response was defined as post-bronchodilator FEV 1 increased by at least 12% and 200 ml. bronchiectasis severity, suggesting that disease severity might not be a modifier of the relationship between LCI and RV/TLC. Therefore, the additive value of normalization with RV/TLC is minimal. Because of airway remodeling and mucus plugging, ventilation heterogeneity and hyperinflation might be reduced following bronchodilation. Unexpectedly, stratifying the LCI and RV/TLC did not reveal different bronchodilator responses. Recent literature suggested that RV more sensitively reflected airway reversibility than spirometric parameters (including FEV 1 ) in obstructive lung disease [25] , and that hyperinflation was associated with greater bronchodilator responses in patients with chronic obstructive pulmonary disease who had poorer lung function [26] . These collectively indicated the potential significance of hyperinflation indices (including RV/TLC) as markers of bronchodilator responses. Contrarily, documentation of different bronchodilator responses when stratified by LCI has not been available. In our study, patients with consistently higher LCI and RV/TLC showed greater disease severity and numerically greater bronchodilator responses, which might have approached statistical significance if sample sizes were further increased. Nevertheless, when specifically focusing on LCI High RV/TLC Low and LCI Low RV/TLC High subgroup, only numerically greater bronchodilator responses were shown in the latter subgroup. However, when analyzing previous records (within 2 years), this trend was slightly tempered. Due to limited sample sizes, we cannot justify the additive value of RV/TLC to LCI in identifying different bronchodilator responses.
Limitations
Our findings are limited by the sample sizes (particularly bronchodilator response) from single research center. No longitudinal follow-up was scheduled to determine temporal stability of LCI or RV/TLC. We did not stratify the levels of LCI based on the previously published "normal values" or the cut-off values derived from receiver operation characteristic curve because all patients in this study demonstrated increased LCI and no healthy subject was enrolled. In light of the "gold standard" for classification, we think that the stratification based on the median levels among all bronchiectasis patients remained to be the alternative approach for classification. The use of MBW for the measurement of LCI might have limited value particularly among patients with severe airflow obstruction or emphysema, in whom the true value of functional residual volume might have been underestimated by the washout methods. Specifically, MBW does not take into account the trapped gas or completely obstructed lung zones. In this study, there lacks a validation of the functional residual capacity using the same pulmonary function testing instrument for LCI measurement. It should be recognized that body plethysmography remains the gold standard for measuring RV/TLC. However, for ease of patient's cooperation, body plethysmography was not additionally performed. The MBW method used in our study has limitations (not validated in this population). There was an absence of age-matched normative data at our local site. We only utilized simple normalization algorithms for adjusting LCI, based on the priori assumption that ventilation heterogeneity could be affected by the magnitude of hyperinflation. Nevertheless, such an attempt remains flawed because nLCI could be simultaneously influenced by different levels of LCI and RV/ TLC, for instance, lower nLCI could be derived from lower LCI plus higher RV/TLC which might be contradictory to our research hypothesis. We cannot fully exclude other more sensitive parameters aside from LCI. However, findings from Haidopoulou et al. have minimized the possibility of deriving more sensitive indices [24] . Additionally, there still might be a bias in the influence of bronchodilation response because it was not assessed in all those with FEV 1 >80%. Finally, the criterion for defining exacerbations was not based on the latest expert consensus, which might have affected some of the data interpretation.
Clinical implications
LCI is a sensitive marker for assessment of bronchiectasis [3] , primary ciliary dyskinesia [27] and CF [20] . From physiological points of view, potential confounding of LCI by RV/TLC cannot be thoroughly excluded. Importantly, our comprehensive analysis has justified the reporting of raw values of LCI against further attempts to normalize with RV/TLC in bronchiectasis. For clinicians, LCI can be reported without further needs to incorporate the levels of RV/TLC. In other words, RV/TLC confers no significant additional benefits for ventilation heterogeneity measurement with LCI. Caution should be exercised when predicting bronchodilator responses with LCI in combination of RV/TLC. Overall, no significant difference was observed when comparing the data among the four subgroups.
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